[go: up one dir, main page]

UA99608C2 - PDGFRb-SPECIFIC INHIBITORS - Google Patents

PDGFRb-SPECIFIC INHIBITORS

Info

Publication number
UA99608C2
UA99608C2 UAA200910244A UAA200910244A UA99608C2 UA 99608 C2 UA99608 C2 UA 99608C2 UA A200910244 A UAA200910244 A UA A200910244A UA A200910244 A UAA200910244 A UA A200910244A UA 99608 C2 UA99608 C2 UA 99608C2
Authority
UA
Ukraine
Prior art keywords
antagonists
pdgfrb
specific inhibitors
pdgfrβ
specific
Prior art date
Application number
UAA200910244A
Other languages
English (en)
Ukrainian (uk)
Inventor
Чженьпин Чжу
Цзюйцюнь Шень
Original Assignee
Имклоун Ллк
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Имклоун Ллк filed Critical Имклоун Ллк
Publication of UA99608C2 publication Critical patent/UA99608C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Fuel Cell (AREA)

Abstract

Заявленное изобретение относится к новым PDGFRβ- специфическим антителам. Антитела применяют для уменьшения или угнетения роста опухолей. Упомянутые антитела могут также вводиться в комбинации с дополнительными противоопухолевыми лекарственными средствами.
UAA200910244A 2007-04-17 2008-04-17 PDGFRb-SPECIFIC INHIBITORS UA99608C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US92397907P 2007-04-17 2007-04-17

Publications (1)

Publication Number Publication Date
UA99608C2 true UA99608C2 (en) 2012-09-10

Family

ID=39837443

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200910244A UA99608C2 (en) 2007-04-17 2008-04-17 PDGFRb-SPECIFIC INHIBITORS

Country Status (14)

Country Link
US (3) US7740850B2 (ru)
EP (1) EP2139921A2 (ru)
JP (1) JP5209702B2 (ru)
KR (1) KR101136262B1 (ru)
CN (1) CN101707882A (ru)
AU (1) AU2008242444B2 (ru)
BR (1) BRPI0810374A2 (ru)
CA (1) CA2682390A1 (ru)
EA (1) EA019595B1 (ru)
IL (1) IL200779A0 (ru)
MX (1) MX2009011226A (ru)
NZ (1) NZ579734A (ru)
UA (1) UA99608C2 (ru)
WO (1) WO2008130704A2 (ru)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2456296T3 (es) 2008-03-27 2014-04-21 Zymogenetics, Inc. Composiciones y procedimientos para inhibir PDGFR beta y VEGF-A
KR20110028258A (ko) * 2008-04-30 2011-03-17 그래댈리스, 인코포레이티드 고순도 플라스미드 ｄｎａ 제제 및 이의 제조방법
US20120231537A1 (en) * 2008-04-30 2012-09-13 Gradalis, Inc. Highly Pure Plasmid DNA Preparations
US20110305672A1 (en) 2008-07-25 2011-12-15 University Of Georgia Research Foundation, Inc. COMPOSITIONS FOR MESODERM DERIVED ISL1+ MULTIPOTENT CELLS (IMPs), EPICARDIAL PROGENITOR CELLS (EPCs) AND MULTIPOTENT CD56C CELLS (C56Cs) AND METHODS OF PRODUCING AND USING SAME
KR20110104052A (ko) 2008-12-16 2011-09-21 노파르티스 아게 효모 디스플레이 시스템
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
AU2010299756A1 (en) * 2009-09-28 2012-04-19 Medizinische Universitat Wien PDGFRbeta inhibitors for use in the treatment of T-cell lymphoma
WO2011075185A1 (en) 2009-12-18 2011-06-23 Oligasis Targeted drug phosphorylcholine polymer conjugates
EP3798236B1 (en) * 2011-03-15 2022-08-10 X-Body, Inc. Antibody screening methods
CN102250249A (zh) * 2011-06-18 2011-11-23 常州亚当生物技术有限公司 一种抗VEGF/PDGFRbeta双特异性抗体及其应用
CA2843158A1 (en) 2011-08-26 2013-03-07 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
EP3712173B1 (en) * 2011-12-05 2023-07-12 X-Body, Inc. Pdgf receptor beta binding polypeptides
TWI613215B (zh) 2012-02-22 2018-02-01 再生元醫藥公司 抗－大－內皮素－１（ｂｉｇ－ｅｔ－１）抗體及其用途
JO3405B1 (ar) * 2013-01-09 2019-10-20 Regeneron Pharma الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها
TW201444872A (zh) 2013-03-06 2014-12-01 Merrimack Pharmaceuticals Inc 抗Ｃ－ＭＥＴ串聯Ｆｃ雙特異性抗體
PT3041513T (pt) 2013-09-08 2020-09-07 Kodiak Sciences Inc Conjugados de polímeros zwiteriónicos com fator viii
US9914769B2 (en) 2014-07-15 2018-03-13 Kymab Limited Precision medicine for cholesterol treatment
DE202014010499U1 (de) 2013-12-17 2015-10-20 Kymab Limited Targeting von humaner PCSK9 zur Cholesterinbehandlung
KR102127408B1 (ko) * 2014-01-29 2020-06-29 삼성전자주식회사 항 Her3 scFv 단편 및 이를 포함하는 항 c-Met/항 Her3 이중 특이 항체
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
KR20210013299A (ko) 2014-10-17 2021-02-03 코디악 사이언시스 인코포레이티드 부티릴콜린에스테라제 양성이온성 중합체 컨쥬게이트
CA2980385A1 (en) 2015-03-20 2016-09-29 Johann Wolfgang Goethe-Universitat Frankfurt Am Main Pericyte long non-coding rnas
WO2017106609A2 (en) * 2015-12-16 2017-06-22 Kadmon Corporation, Llc. Pdgfr beta antibody
WO2017106716A1 (en) 2015-12-16 2017-06-22 Regeneron Pharmaceuticals, Inc. Compositions and methods of manufacturing protein microparticles
CN108712911A (zh) 2015-12-30 2018-10-26 科达制药股份有限公司 抗体及其缀合物
EP3471754A1 (en) 2016-06-20 2019-04-24 Kymab Limited Anti-pd-l1 antibodies
CA3041078A1 (en) * 2016-10-30 2018-05-03 Shanghai Henlius Biotech, Inc. Anti-pd-l1 antibodies and variants
WO2018083248A1 (en) 2016-11-03 2018-05-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11440951B2 (en) 2017-03-13 2022-09-13 The Government Of The United States, As Represented By The Secretary Of The Army Therapeutic antibodies to Marburg virus
CN109021104B (zh) * 2017-06-12 2022-08-12 上海睿智化学研究有限公司 一种抗人血小板衍生生长因子β受体的抗体及其应用
US11795221B2 (en) 2018-02-28 2023-10-24 WuXi Biologics Ireland Limited Monoclonal antibody against human LAG-3, method for preparing the same, and use thereof
WO2019169341A1 (en) 2018-03-02 2019-09-06 Kodiak Sciences Inc. Il-6 antibodies and fusion constructs and conjugates thereof
DE102018204828A1 (de) 2018-03-29 2019-10-02 Ford Global Technologies, Llc Verhinderung von Glatteis durch Abwasser von Kraftfahrzeugen
US11773155B2 (en) 2018-08-09 2023-10-03 Beijing Wisdomab Biotechnology Co., Ltd Bispecific antibody against rabies virus, and application thereof
WO2020071881A1 (ko) * 2018-10-05 2020-04-09 서울대학교산학협력단 Pdgf 수용체에 대한 항체 및 이의 용도
US11912784B2 (en) 2019-10-10 2024-02-27 Kodiak Sciences Inc. Methods of treating an eye disorder
KR20220140551A (ko) * 2020-02-07 2022-10-18 바이오리온 테크놀러지스 비.브이. 혈소판 유래 성장 인자 수용체(pdgfr) 항체, 이의 컨쥬게이트, 조성물 및 용도
CN121399157A (zh) 2023-06-12 2026-01-23 美国安进公司 淋巴毒素β受体激动剂结合蛋白
CN118440214B (zh) * 2024-04-02 2025-01-28 山东大学 一种靶向PDGFRβ的嵌合抗原受体、CAR-T细胞及应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
AU1411092A (en) 1991-01-31 1992-09-07 Cor Therapeutics, Inc. Domains of extracellular region of human platelet derived growth factor receptor polypeptides
US5885793A (en) 1991-12-02 1999-03-23 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
US20020009443A1 (en) * 1991-12-02 2002-01-24 Vanitha Ramakrishman Inhibitory immunoglobulin polypeptides to human pdgf beta receptor
US5817310A (en) 1991-12-02 1998-10-06 Cor Therapeutics, Inc. Inhibitory immunoglobulin polypeptides to human PDGF beta receptor
US5976534A (en) 1993-02-25 1999-11-02 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF receptors and heparin
US5620687A (en) 1993-02-25 1997-04-15 Zymogenetics, Inc. Inhibition of intimal hyperplasia using antibodies to PDGF beta receptors
US5840299A (en) 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US6811779B2 (en) * 1994-02-10 2004-11-02 Imclone Systems Incorporated Methods for reducing tumor growth with VEGF receptor antibody combined with radiation and chemotherapy
US5882644A (en) 1996-03-22 1999-03-16 Protein Design Labs, Inc. Monoclonal antibodies specific for the platelet derived growth factor β receptor and methods of use thereof
US6259971B1 (en) * 1997-06-30 2001-07-10 Compaq Computer Corporation Portable fuel-cell-powered system with ultrasonic atomization of H2O by-product
US7740841B1 (en) * 2000-01-28 2010-06-22 Sunnybrook Health Science Center Therapeutic method for reducing angiogenesis
EP1299419A2 (en) 2000-05-24 2003-04-09 Imclone Systems, Inc. Bispecific immunoglobulin-like antigen binding proteins and method of production
DE50102548D1 (de) * 2000-09-22 2004-07-15 Siemens Ag Verfahren zum überwachen des medienaustritts aus einer brennstoffzelle und brennstoffzellenanlage
EP1313161A1 (en) * 2001-11-15 2003-05-21 Ballard Power Systems AG Fuel cell system and method for operating the same
EP1696949A4 (en) 2003-11-10 2008-02-06 Ghc Res Dev Corp VEGF Receptor Antagonists
EP1786918A4 (en) 2004-07-17 2009-02-11 Imclone Systems Inc NEW BISPECIFIC ANTIBODY TETRAVALENT
WO2008011216A2 (en) 2006-05-16 2008-01-24 Pro-Pharmaceuticals, Inc. Galactose-pronged polysaccharides in a formulation for antifibrotic therapies

Also Published As

Publication number Publication date
US20100221267A1 (en) 2010-09-02
US7740850B2 (en) 2010-06-22
AU2008242444A1 (en) 2008-10-30
AU2008242444B2 (en) 2013-05-02
MX2009011226A (es) 2010-04-01
KR20090130382A (ko) 2009-12-23
WO2008130704A2 (en) 2008-10-30
WO2008130704A3 (en) 2008-12-24
NZ579734A (en) 2012-01-12
IL200779A0 (en) 2010-05-17
JP2010524466A (ja) 2010-07-22
EA019595B1 (ru) 2014-04-30
BRPI0810374A2 (pt) 2014-10-29
CN101707882A (zh) 2010-05-12
EP2139921A2 (en) 2010-01-06
JP5209702B2 (ja) 2013-06-12
KR101136262B1 (ko) 2012-07-05
US20110207005A1 (en) 2011-08-25
CA2682390A1 (en) 2008-10-30
EA200970953A1 (ru) 2010-10-29
US20090053241A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
UA99608C2 (en) PDGFRb-SPECIFIC INHIBITORS
TW201129378A (en) Materials and methods for treating or preventing HER-3 associated diseases
EA201500393A1 (ru) Ингибиторы тирозинкиназы брутона
BR112015020466A2 (pt) inibidores de cdc7
EA201170940A1 (ru) Лечение рака с использованием комбинации бендамустина и анти-cd20-антитела
EA200970935A1 (ru) Способы лечения с применением хинаксолиновых ингибиторов pi3k-альфа
MX361467B (es) Compuestos de isoindolina para uso en el tratamiento de cancer.
BRPI0908635B8 (pt) composto e/ou um sal farmaceuticamente aceitável do mesmo e composição farmacêutica
CL2012000772A1 (es) Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
TR200906131T1 (tr) Aktivin -actrIIa antagonistleri ve göğüs kanserinin tedavi e
EA201201186A1 (ru) ИСПОЛЬЗОВАНИЕ ErbB3 ИНГИБИТОРОВ В ЛЕЧЕНИИ ТРИЖДЫ НЕГАТИВНОГО И БАЗАЛЬНО-ПОДОБНОГО ВИДОВ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
PH12018500641A1 (en) Optimized monoclonal antibodies against tissue factor pathway inhibitor (tfpi)
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
MX2010009669A (es) Terapia de combinacion con antagonistas de c-met y egfr.
SG10201902664RA (en) Combination therapy for treating cancer
MX2017006275A (es) Inhibidor de cinasa aurora a.
EA201201464A1 (ru) Новая комбинированная терапия для лечения онкологических и фиброзных заболеваний
MX2011013424A (es) Metodo de tratamiento del cancer con antagonista dll4 y agente quimioterapeutico.
WO2006102504A3 (en) Combinations for the treatment of cancer comprising anti-egfr antibody and vegfr inhibitors
MX2014004074A (es) Metodo de tratamiento de condiciones del higado utilizando antagonistas de notch2.
EA201101651A1 (ru) Непрерывное введение интегриновых лигандов для лечения рака
MY164998A (en) Isoquinolinone derivatives as nk3 antagonists
EP3991749A3 (en) A therapeutic agent for a tumor comprising an ido inhibitor administered in combination with an antibody
WO2008132500A3 (en) Chkl inhibitors with b cell depleting antibodies for the treatment of hematologic malignancies